1. Medtech Insight

Biden Selects Obama Vet Chiquita Brooks-LaSure To Lead CMS

 
• By Sue Darcey

Former CMS deputy director of policy and regulation Chiquita Brooks-LaSure has been tapped by US President Biden to lead the agency.

Chiquita Brooks-LaSure and Joe Biden
Chiquita Brooks-LaSure, an expert in health policy at the law firm Manatt, Phelps and Philips, is President Biden’s choice to be CMS Administrator

Chiquita Brooks-LaSure, who played a key role in developing the Affordable Care Act, has reportedly been selected by President Joe Biden to lead the US Centers for Medicare and Medicaid Services.

Brooks-LaSure, who served as CMS deputy director of policy and regulation during the Obama administration, now works as a health care policy expert and managing director of Manatt Health, a division of the law firm of Manatt, Phelps and Philips. Administration insiders confirmed the pick to outlets including CNN and The Washington Post

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Medtech Insight

UK Medtech Regulators Must Ensure Certainty So Businesses Can Plan Their Futures

 
• By Ashley Yeo

With medtech businesses typically managing investment cycles on a three- to five-year basis, local regulatory processes and forward costs of market entry must offer an attractive environment in which companies can plan for growth, says McDermott Will and Emery’s partner and head of healthcare and life sciences, Sharon Lamb. Broad-scale improvements to NICE’s evaluation offerings would similarly enhance the UK’s value to innovators.

First At-Home Cervical Cancer Screening Tool Gets FDA Clearance

 
• By Elizabeth Orr

The US FDA has approved the Teal Wand, the first at-home cervical cancer screening device. Capable of detecting preclinical cancer with 96% accuracy, it will launch in California in June and expand nationwide soon after.

SS Innovations Files For De Novo For SSi Mantra 3 Surgical Robotic System For Multispecialty Indications

 
• By Marion Webb

SS Innovations announced plans to file a de novo application with the US FDA for its SSi Mantra 3 surgical robot, already approved for marketing in six countries. The Florida-based firm also plans to pursue the CE mark for European commercialization.